• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    A Biobank for Long-term and Sustainable Research in the Field of Congenital Heart Disease in Germany

    2016-11-17 08:41:13ThomasPickardtEvaNiggemeyerbUlrikeBauerHashimAbdulKhaliqCompetenceNetworkforCongenitalHeartDefectsInvestigators
    Genomics,Proteomics & Bioinformatics 2016年4期

    Thomas Pickardt*,Eva Niggemeyerb,Ulrike M.M.Bauer,c,Hashim Abdul-Khaliq,Competence Network for Congenital Heart Defects Investigators

    1National Register for Congenital Heart Defects,13353 Berlin,Germany

    2Saarland University Medical Center,Department of Paediatric Cardiology,66421 Homburg,Germany

    3Competence Network for Congenital Heart Defects,13353 Berlin,Germany

    RESOURCE REVIEW

    A Biobank for Long-term and Sustainable Research in the Field of Congenital Heart Disease in Germany

    Thomas Pickardt1,*,a,Eva Niggemeyer1,b,Ulrike M.M.Bauer1,3,c,Hashim Abdul-Khaliq2,3,d,Competence Network for Congenital Heart Defects Investigators3

    1National Register for Congenital Heart Defects,13353 Berlin,Germany

    2Saarland University Medical Center,Department of Paediatric Cardiology,66421 Homburg,Germany

    3Competence Network for Congenital Heart Defects,13353 Berlin,Germany

    Received 22 December 2015;revised 14 March 2016;accepted 16 March 2016 Available online 27 April 2016

    Handled by Andreas Keller

    Congenital heart defects;Multi-center research;

    Biorepository;

    Genetic research;

    DNA

    Congenital heart disease(CHD)is the most frequent birth defect(0.8%-1%of all live births).Due to the advance in prenatal and postnatal early diagnosis and treatment,more than 90%of these patients survive into adulthood today.However,several mid-and long-term morbidities are dominating the follow-up of these patients.Due to the rarity and heterogeneity of the phenotypes of CHD,multicenter registry-based studies are required.The CHD-Biobank was established in 2009 with the aim to collect DNA from patients and their parents(trios)or from affected families,as wellas cardiovascular tissues from patients undergoing corrective heartsurgery for cardiovascular malformations.Clinical/phenotype data are matched to the International Paediatric and Congenital Cardiac Code(IPCCC)and the International Statistical Classification of Diseases and Related Health Problems 10th Revision(ICD-10).The DNA collection currently comprises samples from approximately 4200 participants with a wide range of CHD phenotypes. The collection covers about 430 trios and 120 families with more than one affected member.The cardiac tissue collection comprises 1143 tissue samples from 556 patients after open heart surgery.

    The CHD-Biobank provides a comprehensive basis for research in the field of CHD with high standards of data privacy,IT management,and sample logistics.

    Introduction

    Congenital heart disease(CHD)is the most common congenital organ malformation in the neonate.The prevalence of CHD is nearly stable and ranges from 8-10/1000[1,2].Due to the rapid improvement in prenataland postnatalearly diagnosis,as well as the advance in interventional,surgical,and postoperative treatment,the survival of offsprings with CHD has increased dramatically in the last two decades[3-6].Nevertheless,in moderate and severe congenital heart defects,anatomical correction could not be achieved.Intracardiac and extracardiac anatomical and functional residual defects which lead to mid-and long-term morbidities are stillchallenging and limit the long-term survivaland quality of life of these patients[7].

    The etiology of CHD,which is complex and associated with both genetic and environmentalcauses,is stilllargely unknown[8,9].With the growing number of adult CHD patients,information on recurrence risks and understanding the etiology will become increasingly important.Despite the introduction of novel genetic techniques such as next-generation sequencing(NGS),the molecular and genetic mechanisms underlying the development of CHD have not been clearly elucidated yet and the identification of particular defects remains challenging[10,11].

    Moreover,in contrast to the intensive research in the field of ischemic heart failure and the development of therapeutic and preventive approaches in adult patients,the therapeutic and preventive strategies for heart failure in patients with CHD are not adequately established.The molecular mechanisms of myocardial failure in neonatal myocardium after corrective surgery using the cardiopulmonary bypass(CPB),as well as in patients with residual pressure and volume overload,have not been clearly identified yet[12].

    The rarity of such congenital diseases and their heterogeneous morphological phenotypic and morphological manifestation make it difficult to study molecular and genetic origin as well as prevention and treatment[13].Therefore,CHD and its surgical correction are still associated with high mortality in the neonatal life,in contrast to older age groups[14,15].

    Although the neonatal myocardium may still have protective remodeling capacities such as stem cell and myocyte proliferation[16,17],the vulnerability of the neonatal myocardium to ischemia and other risk factors during the surgical manipulation and extracorporeal perfusion by CPB may represent significant risk factors[18,19],leading to myocardial dysfunction after heart surgery.On the other hand,residual adaptive mechanisms of the fetal heart such as cell proliferation and the presence of stem cells have been considered as possible adaptive capacities against stress and ischemic injury[16,17].Data on the remodeling processes in these patients during the transition from fetal to neonatal life are scarce and should be evaluated within the biobank on the basis of a standardized collection of myocardial tissues.

    Thus,the establishment of a nationwide research platform to overcome such challenges in the most common congenital organ malformations in the future is urgently needed. Moreover,extensive research cooperation should not be limited to nationwide research groups,but should also be extended to other countries and performed on an international level,as demonstrated by our network during the past five years(see below,section‘Cooperative projects and partner institutions”).

    Figure1 Structure of CNCHD and NRCHD

    Network and biobank infrastructure

    The CHD-Biobank is an integral part of the National Register for Congenital Heart Defects(www.kompetenznetz-ahf.de/en/ research/register-biobank,hereafter NRCHD),which serves as a core facility of the German Competence Network for Congenital Heart Defects(www.kompetenznetz-ahf.de/en/home,hereafter CNCHD).Both entities are non-profit organizations and operate independently of each other,thus guaranteeing the separation of sustainable and long-term patient data administration and storage on the one hand and research activities on the other hand(Figure 1).The management and coordination for both entities are performed by a central office,the Network Management Office(NMO).The NMO is responsible for patient registration,administration,and consent management.It is also responsible for sample collection,validation of clinical/phenotype data,and research/study management,as well as network communication and operation of database systems.The whole network is headed by a Steering Committee that includes board members from both NRCHD and CNCHD.An essential element of the CHD-Biobank infrastructure is the cooperation with the Central Biomaterial Bank Charite′Berlin(ZeBanC,biobank.charite.de)that carries out central processing of blood and saliva samples and storage of DNA.

    While numerous medical centers and institutions are involved in various studies of the CNCHD,the CHDBiobank project is maintained by eight institutions:the departments of pediatric cardiology and/or heart surgery at the University Hospitals of Kiel,Erlangen,F(xiàn)reiburg,and Homburg,the University Heart Center of Leipzig,the Heartand Diabetes Center NRW(Bad Oeynhausen),the German Heart Centre Munich,and the German Heart Institute Berlin. Further inclusion of more hospitals is scheduled.Participation is bound to the implementation of all required work flows,and the participating institutions confirm the acceptance of CHDBiobank policies and standard operation procedures(SOPs),based on a collaboration agreement.

    Study population

    The CHD-Biobank collects biomaterials from patients with any diagnosed congenital heart defect.For reference analyses,samples of patients’parents(trios)and relatives(from families with an accumulation of CHD)are also included systematically.

    Legal framework—ethics and data privacy

    Based on an appropriate patient informed consent,approval by eight ethics committees in Germany and a data privacy concept(registered with the Berlin Official for Data Protection and Freedom of Information/No.531.390),NRCHD is legally authorized to(i)receive and store medical data and samples from all age groups for an indefinite time,(ii)continuously request latest medical reports from the attending physicians,(iii)re-contact registered participants,(iv)hold the right to use the data and samples collected,and(v)make register data and samples available to interested scientists and research institutions for future studies and within the scope of international cooperation.

    Protection of personal data

    Primary patient codes(pseudonyms)are kept in a separate database(PID-generator,see below)to prevent unauthorized access to re-identifying information.All samples are tagged with a second-level code that is designated only for internal use,i.e.,the processing and storage at the collaborating laboratory facility,where staff members are not able to obtain information on the identity of sample donors or their health conditions.When samples or aliquots of samples are released to research facilities,a third-level code is generated,impeding the re-identification of patients.

    The use of data

    The use of data by research institutions is subject to the CNCHD policies and a material transfer agreement(MTA)that commits data recipients to handle data according to legal regulations and applicable laws,e.g.,preventing third parties from having access to or using samples and data.

    Patients’right of self-determination

    The storage of samples is generally intended for an indefinite time and yet-to-define research purpose.In orderto give patients the opportunity to obtain a continuous update regarding the CHD-Biobank’s research activities(and to withdraw their consent,if required),the NRCHD has implemented a web-based patient information platform(www.herzregister.de).Sample donors can object to the CHD-Biobank’s storing and using their data/samples at any time.Donors can opt between the anonymization and deletion/destruction of data/samples.

    Database systems and ID management

    In consistence with the NRCHD’s overall concept,the CHDBiobank applies a central patient and sample ID management.Patient codes are generated by a so-called PID-generator[20],a software program that creates 8-digit/ alphanumeric pseudonyms on the basis of the patients’personally-identifiable information.The latter is divided into hard and soft criteria and phonetic algorithms,thus ensuring the unambiguity of a patient’s data upon pseudonymization. The PID-generator allows a hospital-independent assignment of patients and facilitates multicenter and longitudinal investigations.

    For clinicaldata and sample acquisition,the NRCHD uses a 3-tier server architecture consisting of Oracle 10g,which is a customized version of ixserv4(ixmid Technologie GmbH,www.ixmid.com),as the application layer,and a Tomcat web server for the presentation layer.The database for biomaterials includes a web frontend with a defined form structure that enables the acquisition of sample-related data(reception,processing,quality,dissemination,tracking,etc.)and facilitates the collection and management of samples from several locations.Sample ID management is performed using uniform barcode-labeling systems including barcoded sample containers with unique alphanumeric codes.

    Clinicaldata

    Clinical data for each participant are obtained via medical reports(doctor’s letters)that are provided by the treating physicians or by the patients themselves.A standardized dataset is recorded from each patient upon registration.The recorded data include(1)personal data:surname,birth name,first name,date of birth,sex,address and contact details,familiar status and relations(acquisition of families),place of birth including federalstate,maritalstatus,and nationality,and(2)medical/phenotype data:maternal age at birth,gestational age,multiple pregnancy,birth weight,prenatal diagnosis of CHD,all congenital and acquired cardiovascular diagnoses,procedures,and additional diseases/disorders.If necessary for accuracy and data validation,further medical findings,e.g.,additional data of magnetic resonance imaging(MRI)/echocardiographic analysis,are requested from the treating physicians.In addition,medical reports are obtained regularly to continuously update/complete the medical database.

    Medical data are coded according to(i)the International Statistical Classification of Diseases and Related Health Problems 10th Revision(ICD-10)and(ii)the International Paediatric and Congenital Cardiac Code(IPCCC)of the International Society for Nomenclature of Pediatric and Congenital Heart Disease comprising 206 different main diagnoses for CHD(Table 1)in order to cover the high variability of CHD phenotypes and conditions.For a rough classification we assign affected sample donors to 29 diagnosis groups(see below,section‘Current state of sample collection”).

    Table1 Comparison between ICD-10 and IPCCC for the classification of congenital heart defects

    Procedures for the collection,processing and storage of samples

    The CHD-Biobank collects EDTA-blood(Sarstedt SMonovette K3E 2.7/4.9/9.0 ml,depending on donor age)and saliva samples(DNAGenotek/Oragene OG-500 and OG-575)for the extraction of DNA,as well as cardiac tissue samples(snap-freezing in liquid nitrogen).The latter are obtained within the scope of open heart surgery during which fractions of tissue accumulate,which would be disposed of otherwise.

    Blood/saliva collection and DNA extraction

    Two means of sample acquisition are in place.Process A is used for the acquisition of blood and saliva samples from patients that are already registered,and their relatives.Patients are contacted by the NMO and asked for participation in the CHD-Biobank project.Adult patients or sample donors,after returning written consent,receive a blood or saliva sample kit. For blood taking,sample donors address a physician of their choice.Blood or saliva samples are sent to ZeBanC.Process A is most suitable for recruiting families and twins via direct contact to participants of the NRCHD.On the other hand,Process B is used for the acquisition of blood samples from patients not yettaking partin the NRCHD.Collaborating hospitals are regularly provided by the NMO with blood kits that include coded documents(informed consent and sample data sheets)and barcoded sample containers that are linked to the respective documents(recorded in the CHD-Biobank database).Within the scope of scheduled examinations,patients are informed and blood withdrawal takes place if they agree.The responsible physician forwards the signed consent form together with a medicalreport to the NMO,and the blood sample to ZeBanC.

    A small amount of blood sample is retained for control purposes and stored at-80°C.Saliva and the remaining blood samples are further processed at ZeBanC.For the automated extraction of DNA from blood and saliva,ZeBanC uses the Freedom EVO HSM 2.0 Workstation and the ReliaPrep Large Volume HTgDNA Isolation System(Promega/Tecan).The processing,aliquoting,and storage of samples are documented via the online-accessible CHD-Biobank database.The documented data include information with respect to the date of blood taking,dispatch and arrival,blood volume/quality,extraction-related information/specifications,DNA purity,gel-quality check,concentration,volume and aliquotting. DNA is stored at-20°C.

    Figure2 Tissue-sample collection kit

    Tissue samples from open heart surgery

    The NMO provides specific tissue sample kits(Figure 2)for all participating departments.A sample kit comprises fivecryotubes(FluidX,1.8 ml),each of which is provided with a unique identifier(2D+1D barcodes),and a standardized sample acquisition form,tagged with the identifiers of the above tubes,printed as 1D-barcodes.Tubes and acquisition form are therefore already linked prior to their usage. Moreover,the acquisition form contains a list of heart tissue types that have been pre-defined by the Network surgeons.

    When tissue kits are allocated to a certain patient,the surgical team can collect tissue samples without the need of further marking/labeling tubes.The type of tissue that is placed in one of the five tubes is readily designated:tube caps contain inserts in different colors which are reproduced as dots alongside the list of tissue types;then the corresponding dot just has to be ticked on the acquisition form.

    Samples are snap-frozen in liquid nitrogen and then stored in the gas phase of liquid nitrogen.The samples are stored in local facilities at the participating medical centers.All sample data(vial code,type of tissue,acquisition date,position in the nitrogen-storage container)are entered electronically via web interface into the CHD-Biobank database.

    Sample quality management

    All work flows have been defined in SOPs and are revised and adjusted continuously according to technological progress. SOPs conform to or are based on the International Society for Biological and Environmental Repositories(ISBER)recommendations(http://www.isber.org).The following measures have been introduced in order to maintain high quality standards regarding the logistics and infrastructure of the CHDBiobank.

    Uniform protocols and work flows

    The NMO team provides an efficient data and sample management,the implementation of harmonized protocols and work flows,standardized logistics,efficient central administration,and a continuous risk assessment.

    Guideline-based patient contact

    Recruitment of patients and families is accompanied by substantial guideline-based telephone interviews performed by NMO staff members that are specifically instructed and allowed to initiate and hold contact to register participants.

    On-site visits

    Participating hospitals are controlled through on-site visits by NMO staff members at least once a year,including the instruction of hospitalstaff members involved in data and sample collection,as well as documentation.

    Permanent availability and support

    The NMO team permanently keeps in touch with the responsible hospital staff members and provides them with support.

    Web-based data entry

    Information relevant to sample quality,acquisition,and processing procedures is recorded in the online-accessible CHD-Biobank database.The NMO team monitors data entry in realtime.

    Use of 1D/2D barcodes

    For nitrogen storage of samples,F(xiàn)luidX Cryovials with 2D-barcode jackets are used.The identification and recording of samples occur via barcode reading(linear-and 2D-barcode readers)only.

    Secure nitrogen storage and handling

    For tissue storage,the CHD-Biobank is equipped with Cryotherm Biosafe 120 MD containers providing an onlineaccessible,permanent all-over control and complete documentation of temperature and nitrogen filling status. For incorporating and disseminating samples,a working procedure preventing thawing and refreezing has been implemented.

    Network policies and use of the sample collection

    The NRCHD is a sustainable legal entity that is eligible to receive,store,and use data and samples from patients with CHD for research purposes.The sample donors transfer the right to use their biomaterials for scientific purposes to the NRCHD,which reserves the right to use as long as sample donors do not withdraw their consent.

    Use and access regulations and policies(see www.kompetenznetz-ahf.de/en/research/initiating-new-projects)comprise(i)general rules for cooperative studies,(ii)defined forms/ templates for research proposals,(iii)a defined description of the decision process,and(iv)publication guidelines.

    The CHD-Biobank offers researchers both the option of using existing samples and associated demographic and medical data,as well as the option of utilizing the CHD-Biobank infrastructure for a prospective recruitment of sample donors for specific studies.This service is open to all researchers or scientists with relevant expertise in the field of genetics and CHD and is not limited to members of the CNCHD.

    In order to participate,researchers have to submit a research proposal to the NMO.Research proposals are evaluated by the Scientific Board,which consists of experts in the fields of(pediatric)cardiology,epidemiology,human genetics,basic research,biometry/statistics,and ethics/health care law. Moreover,the Board comprises a representative of the German umbrella organization for children with CHD(BVHK e.V.).The final decision is made by the Steering Committee of the CNCHD and the representatives of the institutions where the samples have been collected,based on criteria such as a project’s feasibility,the precisely-defined objective,acceptance within the CHD research community,and stringent scheduling.Appropriate expertise in the field of interest is therefore a prerequisite.

    Upon approval,collaborating research groups and institutions must agree to make,after completion and publicationof their study,exploitable data such as sequence data available for being used by research groups in future studies.

    Sustainability

    Since January 2015,the NRCHD is supported by the newly established German Center for Cardiovascular Research(DZHK).Within this close cooperation,a comprehensive sustainable research network could be established,which covers congenital and acquired cardiovascular diseases in children and adults.

    Table2 Outline of the current CHD-Biobank DNA collection

    Figure3 Age distribution of the affected donors

    Table3 Distribution of the affected donors by diagnosis groups

    Current state of sample collection

    Table 2 gives an outline of the current DNA collection of the CHD-Biobank(as of March 2016):the collection comprises DNA samples from 4602 donors,including 2928 affected donors,covering a wide range of CHD phenotypes.1674 donors are non-affected relatives,since the CHD-Biobank focuses on the inclusion of whole families when more than one affected member is present,and the enrollment of trios(affected children and their healthy parents).In addition to family and trio samples,the inclusion of twins is crucial for research on etiology and genetic factors of CHDs as well. The CHD-Biobank recruits families and twins mainly by direct contact to registered participants via Process A(as described in section‘‘Blood/saliva collection and DNA extraction”).

    The breakdown of sample donors by age groups(Figure 3,documented age when samples were taken)reveals the predominance of underage patients(0-17 years),which represent more than 70%of the affected donors.

    Table 3 shows the distribution of the 29 diagnosis groups that we use for rough classification of the affected donors. The distribution does not reflect the average distribution of CHDs,since the CHD-Biobank focuses mainly on medium or severe,complex heart defects.

    While the majority of children born with CHDs do not have other birth defects(isolated CHD),20%-30%of cases occur in association with other,extracardiac anomalies or as part of a syndrome(syndromic CHD).Figure 4 shows the distribution of syndromes/disorders among the affected donors in the CHD-Biobank.

    For DNA extraction,9 ml of blood are withdrawn from adults.In acordance with the German ethical guidelines regarding underage participants,amounts of maximally 9 ml(age 3-17),5 ml(age 1-3),and 2.5 ml(below age 1)of blood are taken.Moreover,the ethics commission specifies that blood to be used for scientific purposes may only be taken from underage patients within the scope of a medicalexamination.We therefore additionally implemented saliva sample kits(DNAGenotek,Oragene,standard amount of 2 ml saliva)for DNA acquisition from affected,underage donors beyond medical examinations and for non-affected siblings.

    Figure4 Distribution of the affected donors born with additional syndromes/disorders

    Figure5 Type and number of tissue samples from heart surgery

    The automated extraction method for EDTA-blood on average yields 15.2μg DNA from 1 ml EDTA-blood and 16.8μg DNA from 1 ml of saliva.In addition to the routine control via gel electrophoresis and absorbance ratios 260/280 and 260/230 nm,the quality of DNAfrom 1147 sample donors has been checked within the scope of the cooperative project with the Wellcome Trust Sanger Institute(WTSI,Cambridge/UK).In more than 98%of samples,whole exome-or panel-sequencing was successful.

    Figure 5 shows the tissue samples that have been collected so far at the heart surgery departments of the university hospitals of Kiel,Erlangen,and Saarland/Homburg,as well as the German Heart Institute in Berlin.In total,1295 tissue samples have been collected from 659 patients,which are listed in Figure 5 according to the tissue type.An RNA quality control analysis of 20 tissue samples within the scope of our cooperative project with the Department of Pediatric Cardiology and Critical Care at Hannover Medical School revealed RNA integrity number(RIN)values of 8.2-9.4,indicating a high quality of the RNA generated.

    Cooperative projects and partner institutions

    At the time when the CHD-Biobank was initiated(2008/09),research on CHD genetics was only slightly established in Germany,partially due to the limited availability of samples. We therefore started cooperative projects on an international levelfrom the beginning.A number of projects have since thenbeen completed and further projects are in progress or in preparation.Projects include candidate gene approaches,chip-based copy number variation(CNV)analysis,and various NGS approaches.Up to now,a total of 1588 DNA samples of the affected and non-affected donors,as well as 36 tissue samples from heart surgery,have been provided for various research studies(Table 4).

    Table4 Cooperative projects and partner institutions

    Conclusions

    Research activities including molecular mechanisms of the development of cardiovascular malformations and several associated long-term morbidities are increasingly becoming a substantialsubject of genetic studies,largely due to sequencing capacities being available and a more routine use of bioinformatic analysis techniques.

    The identification of the causes and underlying molecular genetic processes,and an improved understanding of the pathologic mechanisms of long-term morbidities,are the prerequisites of developing new prevention strategies and treatment methods for patients with CHD.In particular,for patients with moderate and severe CHD in their early life,morbidities after successful operative treatment are now challenging their long-term survival and quality of life.Unfortunately,there are only scarce data on molecular mechanisms underlying myocardial systolic and diastolic dysfunction and possible therapeutic targets in the left and right ventricle. Similarly,data from patients having a morphologically single ventricle with heterogeneous anatomy are rare as well. The genetic mechanisms underlying several extracardiac morbidities,including hypoplasia and inadequate pulmonary growth in patients with restricted pulmonary perfusion,rapid growth and dilatation of the ascended aorta in patients with univentricular heart or tetralogy of Fallot and pulmonary atresia,are currently unknown.Thus,prospective clinical and genetic trials in larger cohorts are needed.These can only be performed on the basis of a nationwide registry and biobank.

    The CHD-Biobank includes comprehensive representative genetic materials of patients and their parents as well as further relatives,covering severe and mild CHD.The Network Management Team is currently increasing the efforts to include more families with accumulation of congenital cardiomyopathies.

    The rising number of requests for collaboration from numerous national and international research institutions can be regarded as an indication for the high quality of samples and phenotype data deposited in our biobank.

    The described biobank may represent a future platform for prospectively recruiting cohorts of patients with complex CHD,including the comprehensive phenotypic and genetic characterization in early childhood,as well as repeated clinical and cardiac follow-up and assessments at standardized time intervals.Such an approach may be the basis to develop individualized medical treatment and care for patients with these rare and complex CHDs.

    Authors’contributions

    TP,EN,UMMB,and HAK have made equal contributions to the biobank concept and design,and preparation of the manuscript.HAK is the Speaker of the Network and UMMB is the Managing Director of the Network.Allauthors have read and approved the final manuscript.

    Competing interests

    The authors declare that there are no competing interests.

    Acknowledgments

    The authors are grateful to all sample donors who participated in the CHD-Biobank.We thank the following collection sites: Herz-und Diabeteszentrum NRW/Bad Oeynhausen,Kinderherzzentrum/Zentrum fu¨r angeborene Herzfehler,Klinik fu¨r Kinderkardiologie und angeborene Herzfehler(D.Kececioglu),Klinik fu¨r Kinderherzchirurgie und angeborene Herzfehler(E.Sandica);Deutsches Herzzentrum Berlin,Klinik fu¨r angeborene Herzfehler und Kinderkardiologie(F.Berger,O. Miera,S.Ovroutski,B.Peters,K.Schmitt,S.Schubert),Klinik fu¨r die Chirurgie Angeborener Herzfehler/Kinderherzchirurgie(J.Photiadis);Universita¨tsklinikum Erlangen/ Friedrich-Alexander-Universita¨t Erlangen-Nu¨rnberg,Kinderkardiologische Abteilung(S.Dittrich,O.Toka),Medizinische Klinik 2-Kardiologie und Angiologie(U.Gundlach),Kinderherzchirurgische Abteilung(R.Cesnjevar);Universita¨ts-Herzzentrum Freiburg Bad Krozingen/Freiburg,Zentrum fu¨r Kinder-und Jugendmedizin,Klinik fu¨r Angeborene Herzfehler/Pa¨diatrische Kardiologie(B.Stiller),Klinik fu¨r Herz-und Gefa¨?chirurgie(F.Beyersdorf),Klinik fu¨r Herzund Gefa¨?chirurgie,Sektion Kinderherzchirurgie(J.Kroll);Universita¨tsklinikum Schleswig-Holstein/Kiel,Klinik fu¨r angeborene Herzfehler und Kinderkardiologie(H.H.Kramer,J.T.Cremer),Klinik fu¨r Herz-und Gefa¨?chirurgie(J. Scheewe);Herzzentrum Leipzig,Klinik fu¨r Kinderkardiologie(I.Da¨hnert,P.Kinzel),Klinik fu¨r Herzchirurgie/Kinderherz chirurgie(M.Kostelka);Deutsches Herzzentrum Mu¨nchen,Klinik fu¨r Kinderkardiologie und Angeborene Herzfehler(P. Ewert,A.Hager,H.Kaemmerer,N.Nagdyman,J.Schoetzau),Klinik fu¨r Herz-und Gefa¨?chirurgie(R.Lange).Universita¨tsklinikum des Saarlandes/Homburg,Klinik fu¨r Pa¨diatrische Kardiologie(T.Ra¨dle-Hurst,A.Rentzsch),Klinik fu¨r Thorax-und Herz-Gefa¨?-Chirurgie(H.J.Scha¨fers). We would like to acknowledge the excellent cooperation with our partner biobank Central Biomaterial Bank Charite′Berlin,ZeBanC for sample processing and storage of biomaterials. This work was supported by the Competence Network for Congenital Heart Defects which is funded by the Federal Ministry of Education and Research of Germany(BMBF;Grant No.01GI0601)until 2014 and,in part,supported by the DZHK(German Centre for Cardiovascular Research)(as of 2015).

    [1]Hoffman JI,Kaplan S.The incidence of congenital heart disease. J Am Coll Cardiol 2002;39:1890-900.

    [2]Schwedler G,Lindinger A,Lange PE,Sax U,Olchvary J,Peters B,et al.Frequency and spectrum of congenital heart defects among live births in Germany:a study of the competence network for congenital heart defects.Clin Res Cardiol 2011;100:1111-7.

    [3]Marelli AJ,Mackie AS,Ionescu-Ittu R,Rahme E,Pilote L. Congenital heart disease in the general population:changing prevalence and age distribution.Circulation 2007;115:163-7.

    [4]Kovacs AH,Verstappen A.The whole adult congenital heart disease patient.Prog Cardiovasc Dis 2011;53:247-53.

    [5]Sable C,F(xiàn)oster E,Uzark K,Bjornsen K,Canobbio MM,Connolly HM,et al.Best practices in managing transition to adulthood for adolescents with congenital heart disease:the transition process and medicaland psychosocialissues:a scientific statement from the American Heart Association.Circulation 2011;123:1454-85.

    [6]Moons P,Bovijn L,Budts W,Belmans A,Gewillig M.Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in Belgium.Circulation 2010;122:2264-72.

    [7]Tennant PW,Pearce MS,Bythell M,Rankin J.20-year survival of children born with congenital anomalies:a population-based study.Lancet 2010;375:649-56.

    [8]Zhu H,Kartiko S,F(xiàn)innell RH.Importance of gene-environment interactions in the etiology of selected birth defects.Clin Genet 2009;75:409-23.

    [9]Ou Y,Mai J,Zhuang J,Liu X,Wu Y,Gao X,et al.Risk factors of different congenital heart defects in Guangdong,China.Pediatr Res 2016;79:549-58.

    [10]Gelb BD,Chung WK.Complex genetics and the etiology of human congenital heart disease.Cold Spring Harb Perspect Med 2014;4:a013953.

    [11]Lalani SR,Belmont JW.Genetic basis of congenital cardiovascular malformations.Eur J Med Genet 2014;57:402-13.

    [12]Reddy S,Bernstein D.Molecular mechanisms of right ventricular failure.Circulation 2015;132:1734-42.

    [13]Marian AJ.Copy number variants and the genetic enigma of congenital heart disease.Circ Res 2014;115:821-3.

    [14]Wang Y,Liu G,Canfield MA,Mai CT,Gilboa SM,Meyer RE,et al.Racial/ethnic differences in survival of United States children with birth defects:a population-based study.J Pediatr 2015;166:819-26.

    [15]Benziger CP,Stout K,Zaragoza-Macias E,Bertozzi-Villa A,F(xiàn)laxman AD.Projected growth of the adult congenital heart disease population in the United States to 2050:an integrative systems modeling approach.Popul Health Metr 2015;13:29.

    [16]Simpson DL,Mishra R,Sharma S,Goh SK,Deshmukh S,Kaushal S.A strong regenerative ability of cardiac stem cells derived from neonatal hearts.Circulation 2012;126:46-53.

    [17]Mahmoud AI,Kocabas F,Muralidhar SA,Kimura W,Koura AS,Thet S,et al.Meis1 regulates postnatal cardiomyocyte cell cycle arrest.Nature 2013;497:249-53.

    [18]Karimi M,Wang LX,Hammel JM,Mascio CE,Abdulhamid M,Barner EW,et al.Neonatal vulnerability to ischemia and reperfusion:cardioplegic arrest causes greater myocardial apoptosis in neonatal lambs than in mature lambs.J Thorac Cardiovasc Surg 2004;127:490-7.

    [19]Gombosova I,Boknik P,Kirchhefer U,Knapp J,Luss H,Muller FU,et al.Postnatal changes in contractile time parameters,calcium regulatory proteins,and phosphates.Am J Physiol 1998;274:H2123-32.

    [20]Faldum A,Pommerening K.An optimal code for patient identifiers.Comput Methods Programs Biomed 2005;79:81-8.

    [21]Postma AV,van Engelen K,van de Meerakker J,Rahman T,Probst S,Baars MJ,et al.Mutations in the sarcomere gene MYH7 in Ebstein anomaly.Circ Cardiovasc Genet 2011;4:43-50.

    [22]van Engelen K,Postma AV,van de Meerakker J,Roos-Hesselink JW,Helderman-van den Enden AT,et al.Ebstein anomaly may be caused by mutations in the sarcomere protein gene MYH7. Neth Heart J 2013;21:113-7.

    [23]Tagariello A,Breuer C,Birkner Y,Schmidt S,Koch A,Cesnjevar R,et al.Functional null mutations in the gonosomal homologue gene TBL1Y are associated with non-syndromic coarctation of the aorta.Curr Mol Med 2012;2:199-205.

    [24]Arndt AK,Schafer S,Drenckhahn JD,Sabeh MK,Plovie ER,Caliebe A,et al.Fine mapping of the 1p36 deletion syndromeidentifies mutation of PRDM16 as a cause of cardiomyopathy. Am J Hum Genet 2013;93:67-77.

    [25]Bansal V,Dorn C,Grunert M,Klaassen S,Hetzer R,Berger F,et al.Outlier-based identification of copy number variations using targeted resequencing in a small cohort of patients with tetralogy of Fallot.PLoS One 2014;9:e85375.

    [26]Al Turki S,Manickaraj AK,Mercer CL,Gerety S,Hitz MP,Lindsay S,et al.Rare variants in NR2F2 cause congenital heart defects in humans.Am J Hum Genet 2014;94:574-85.

    [27]Moosmann J,Uebe S,Dittrich S,Ru¨ffer A,Ekici AB,Toka O. Novellocifor non-syndromic coarctation of the aorta in sporadic and familial cases.PLoS One 2015;10:e0126873.

    *Corresponding author.

    E-mail:pickardt@kompetenznetz-ahf.de(Pickardt T).

    aORCID:0000-0003-0019-6325.

    bORCID:0000-0001-6590-8034.

    cORCID:0000-0002-6317-3609.

    dORCID:0000-0002-5752-5866.

    Peer review under responsibility of Beijing Institute of Genomics,Chinese Academy of Sciences and Genetics Society of China.

    http://dx.doi.org/10.1016/j.gpb.2016.03.003

    1672-0229?2016 The Authors.Production and hosting by Elsevier B.V.on behalf of Beijing Institute of Genomics,Chinese Academy of Sciences and Genetics Society of China.

    This is an open access article under the CC BY license(http://creativecommons.org/licenses/by/4.0/).

    国产成人免费无遮挡视频| 美女大奶头视频| 在线永久观看黄色视频| 一级片免费观看大全| 成年人黄色毛片网站| 午夜久久久在线观看| 美国免费a级毛片| 国产99白浆流出| 欧美黑人精品巨大| 亚洲黑人精品在线| svipshipincom国产片| 国产精品久久久久成人av| 黑人巨大精品欧美一区二区蜜桃| 国产免费现黄频在线看| 国产精华一区二区三区| 怎么达到女性高潮| 亚洲一区二区三区色噜噜 | 一级,二级,三级黄色视频| 中文字幕色久视频| 9热在线视频观看99| 美女大奶头视频| 久久中文字幕一级| 老司机午夜福利在线观看视频| 日日爽夜夜爽网站| 99国产极品粉嫩在线观看| 久久狼人影院| 另类亚洲欧美激情| 999久久久精品免费观看国产| 亚洲精品一区av在线观看| 亚洲全国av大片| 黄色 视频免费看| 99久久久亚洲精品蜜臀av| 成人特级黄色片久久久久久久| 国产无遮挡羞羞视频在线观看| 精品少妇一区二区三区视频日本电影| 12—13女人毛片做爰片一| 亚洲第一av免费看| 亚洲精品一二三| 亚洲av日韩精品久久久久久密| 亚洲性夜色夜夜综合| 露出奶头的视频| 99精国产麻豆久久婷婷| 国产一区二区激情短视频| 婷婷六月久久综合丁香| 日韩成人在线观看一区二区三区| av天堂在线播放| 成人国产一区最新在线观看| 黑人巨大精品欧美一区二区mp4| 欧美激情久久久久久爽电影 | 国产一区二区三区视频了| 最好的美女福利视频网| 天天影视国产精品| 日韩大尺度精品在线看网址 | 桃红色精品国产亚洲av| 一个人免费在线观看的高清视频| 大型av网站在线播放| 免费看十八禁软件| 日本wwww免费看| 久久影院123| 99久久99久久久精品蜜桃| 激情视频va一区二区三区| 久久久久亚洲av毛片大全| 999久久久国产精品视频| 婷婷精品国产亚洲av在线| 午夜免费成人在线视频| 亚洲伊人色综图| 宅男免费午夜| 欧美激情极品国产一区二区三区| 久久人妻福利社区极品人妻图片| 国产亚洲欧美在线一区二区| 亚洲av美国av| 国产亚洲欧美在线一区二区| 成人亚洲精品一区在线观看| 91成年电影在线观看| 91av网站免费观看| 色综合站精品国产| 成在线人永久免费视频| 在线看a的网站| 母亲3免费完整高清在线观看| 国产精品 国内视频| 亚洲人成电影观看| 午夜精品久久久久久毛片777| 精品日产1卡2卡| 日韩精品中文字幕看吧| 1024香蕉在线观看| 99香蕉大伊视频| 男男h啪啪无遮挡| 神马国产精品三级电影在线观看 | 国产精品乱码一区二三区的特点 | 久久久久久久久久久久大奶| 亚洲在线自拍视频| 99国产极品粉嫩在线观看| 亚洲性夜色夜夜综合| 狂野欧美激情性xxxx| 亚洲va日本ⅴa欧美va伊人久久| 在线观看一区二区三区激情| 嫁个100分男人电影在线观看| 亚洲在线自拍视频| 三上悠亚av全集在线观看| 亚洲精品美女久久av网站| 午夜精品久久久久久毛片777| 真人做人爱边吃奶动态| 国产又色又爽无遮挡免费看| 欧美精品一区二区免费开放| 亚洲av成人一区二区三| 国产又爽黄色视频| 亚洲第一欧美日韩一区二区三区| 91九色精品人成在线观看| 村上凉子中文字幕在线| 久久久久九九精品影院| 国产1区2区3区精品| 99久久人妻综合| 丝袜美腿诱惑在线| 在线播放国产精品三级| 老熟妇仑乱视频hdxx| 露出奶头的视频| 可以免费在线观看a视频的电影网站| 757午夜福利合集在线观看| 男人舔女人下体高潮全视频| 成年人黄色毛片网站| 99国产精品99久久久久| 一a级毛片在线观看| www.www免费av| 欧美最黄视频在线播放免费 | 亚洲一卡2卡3卡4卡5卡精品中文| 中文字幕精品免费在线观看视频| 日韩欧美三级三区| e午夜精品久久久久久久| 色婷婷久久久亚洲欧美| 男女床上黄色一级片免费看| 少妇的丰满在线观看| 午夜激情av网站| 亚洲,欧美精品.| 久久久国产成人免费| 在线观看舔阴道视频| 亚洲国产看品久久| 欧美日韩一级在线毛片| 久久久久国产精品人妻aⅴ院| 少妇被粗大的猛进出69影院| 视频区图区小说| 99国产精品一区二区三区| 丰满的人妻完整版| 无人区码免费观看不卡| 九色亚洲精品在线播放| 午夜福利免费观看在线| √禁漫天堂资源中文www| 亚洲欧美激情在线| 国产精品av久久久久免费| 人妻久久中文字幕网| 久久国产精品影院| 国产三级黄色录像| 欧洲精品卡2卡3卡4卡5卡区| 日韩欧美国产一区二区入口| 最近最新免费中文字幕在线| 男男h啪啪无遮挡| 啦啦啦免费观看视频1| 十八禁人妻一区二区| 国产1区2区3区精品| 国产在线观看jvid| 久久精品亚洲av国产电影网| 韩国av一区二区三区四区| 国产一区在线观看成人免费| 久久香蕉激情| 欧美日韩av久久| 欧美黑人欧美精品刺激| 老司机福利观看| 亚洲精品一卡2卡三卡4卡5卡| www.999成人在线观看| 最新在线观看一区二区三区| 女同久久另类99精品国产91| 亚洲性夜色夜夜综合| 国产精品 欧美亚洲| 国产高清视频在线播放一区| 亚洲精华国产精华精| 99精品在免费线老司机午夜| 男女下面进入的视频免费午夜 | 啦啦啦 在线观看视频| 夜夜夜夜夜久久久久| 亚洲专区国产一区二区| 国产精品av久久久久免费| 在线播放国产精品三级| 日韩成人在线观看一区二区三区| 别揉我奶头~嗯~啊~动态视频| 高清欧美精品videossex| 国产欧美日韩一区二区三| 亚洲人成电影免费在线| 久久国产精品影院| 午夜亚洲福利在线播放| 可以在线观看毛片的网站| 美女大奶头视频| 这个男人来自地球电影免费观看| 中文字幕高清在线视频| a级片在线免费高清观看视频| x7x7x7水蜜桃| 激情视频va一区二区三区| 国产av精品麻豆| 久久伊人香网站| 纯流量卡能插随身wifi吗| 久久人妻熟女aⅴ| 9色porny在线观看| 精品一区二区三卡| 国产成人一区二区三区免费视频网站| 成人特级黄色片久久久久久久| 成在线人永久免费视频| av国产精品久久久久影院| 搡老岳熟女国产| 欧美日韩视频精品一区| 777久久人妻少妇嫩草av网站| 99热只有精品国产| 麻豆av在线久日| 亚洲欧美精品综合久久99| 精品久久久精品久久久| 91麻豆精品激情在线观看国产 | 国产高清激情床上av| 操出白浆在线播放| 亚洲色图av天堂| 欧美日韩中文字幕国产精品一区二区三区 | 日韩人妻精品一区2区三区| 亚洲色图综合在线观看| 久久精品国产清高在天天线| 欧美成人免费av一区二区三区| 精品一区二区三区视频在线观看免费 | 日本wwww免费看| 亚洲五月色婷婷综合| 国产成人精品在线电影| 我的亚洲天堂| 午夜免费观看网址| 亚洲成a人片在线一区二区| 777久久人妻少妇嫩草av网站| 久久久国产精品麻豆| 国产片内射在线| 最好的美女福利视频网| 欧美乱妇无乱码| 精品高清国产在线一区| 老汉色av国产亚洲站长工具| 精品午夜福利视频在线观看一区| 亚洲av成人不卡在线观看播放网| 真人一进一出gif抽搐免费| 久久精品亚洲熟妇少妇任你| 90打野战视频偷拍视频| 久久热在线av| 日韩欧美一区视频在线观看| 亚洲成国产人片在线观看| 色哟哟哟哟哟哟| 国产精品久久久久久人妻精品电影| 50天的宝宝边吃奶边哭怎么回事| 丰满的人妻完整版| 免费久久久久久久精品成人欧美视频| 午夜影院日韩av| 波多野结衣一区麻豆| 手机成人av网站| 精品久久久久久久毛片微露脸| 国产aⅴ精品一区二区三区波| 亚洲美女黄片视频| 精品一区二区三区四区五区乱码| 国产视频一区二区在线看| 国产欧美日韩一区二区三| 女人被狂操c到高潮| 免费在线观看影片大全网站| 大香蕉久久成人网| 国产精品99久久99久久久不卡| 亚洲性夜色夜夜综合| 制服人妻中文乱码| 日韩欧美一区二区三区在线观看| 婷婷丁香在线五月| 在线视频色国产色| 日本撒尿小便嘘嘘汇集6| 亚洲中文字幕日韩| a级毛片在线看网站| 看黄色毛片网站| 亚洲久久久国产精品| 操美女的视频在线观看| 久久精品亚洲精品国产色婷小说| 天天躁狠狠躁夜夜躁狠狠躁| 男人的好看免费观看在线视频 | 国产精品 国内视频| 精品久久久精品久久久| 天堂动漫精品| 久久人人爽av亚洲精品天堂| 另类亚洲欧美激情| 免费久久久久久久精品成人欧美视频| 国产xxxxx性猛交| 三级毛片av免费| 热re99久久精品国产66热6| 亚洲黑人精品在线| 色老头精品视频在线观看| 黑丝袜美女国产一区| 黑人欧美特级aaaaaa片| 天天影视国产精品| 老司机午夜福利在线观看视频| 自线自在国产av| 欧美精品一区二区免费开放| 精品国产亚洲在线| 亚洲五月婷婷丁香| 中文亚洲av片在线观看爽| 人成视频在线观看免费观看| 亚洲一区中文字幕在线| 午夜亚洲福利在线播放| 午夜91福利影院| 国产精品二区激情视频| 91老司机精品| 亚洲第一青青草原| 亚洲欧洲精品一区二区精品久久久| 亚洲第一av免费看| 欧美一级毛片孕妇| 国产在线观看jvid| 91麻豆av在线| 午夜福利欧美成人| 精品日产1卡2卡| 欧美日本亚洲视频在线播放| 精品无人区乱码1区二区| 女人被躁到高潮嗷嗷叫费观| 国产av又大| 久久国产精品影院| 又大又爽又粗| 夜夜看夜夜爽夜夜摸 | 精品卡一卡二卡四卡免费| 99在线人妻在线中文字幕| 午夜久久久在线观看| 99久久久亚洲精品蜜臀av| 久久精品91无色码中文字幕| 一本大道久久a久久精品| 女性生殖器流出的白浆| 精品一区二区三区av网在线观看| 一进一出好大好爽视频| 国产av一区在线观看免费| 国产精品香港三级国产av潘金莲| 首页视频小说图片口味搜索| 亚洲精品一区av在线观看| 国产国语露脸激情在线看| 妹子高潮喷水视频| 日韩大码丰满熟妇| 黄网站色视频无遮挡免费观看| 久久精品91无色码中文字幕| 老熟妇乱子伦视频在线观看| 亚洲国产精品一区二区三区在线| 女性被躁到高潮视频| 午夜福利在线免费观看网站| 中文字幕高清在线视频| 久久久精品欧美日韩精品| 亚洲精品久久午夜乱码| 亚洲成av片中文字幕在线观看| 中文字幕最新亚洲高清| a级片在线免费高清观看视频| 亚洲精品国产色婷婷电影| 男女下面进入的视频免费午夜 | 久久亚洲真实| 我的亚洲天堂| 亚洲精品美女久久久久99蜜臀| 亚洲在线自拍视频| ponron亚洲| 国产av又大| 亚洲中文字幕日韩| 如日韩欧美国产精品一区二区三区| 曰老女人黄片| 大型av网站在线播放| 女性被躁到高潮视频| 亚洲av第一区精品v没综合| 咕卡用的链子| 91成年电影在线观看| 成人精品一区二区免费| 亚洲精品粉嫩美女一区| 国产1区2区3区精品| 亚洲中文av在线| 国产激情欧美一区二区| 国产免费现黄频在线看| 亚洲av片天天在线观看| 99国产综合亚洲精品| 精品卡一卡二卡四卡免费| 亚洲人成77777在线视频| 看黄色毛片网站| 露出奶头的视频| 亚洲午夜理论影院| 99精国产麻豆久久婷婷| 日韩免费高清中文字幕av| 亚洲九九香蕉| 亚洲一区二区三区不卡视频| 99国产综合亚洲精品| 国产亚洲精品综合一区在线观看 | 一本大道久久a久久精品| 欧美日韩乱码在线| 手机成人av网站| 亚洲国产欧美一区二区综合| 夜夜看夜夜爽夜夜摸 | 亚洲精品一卡2卡三卡4卡5卡| 亚洲国产欧美一区二区综合| 黄网站色视频无遮挡免费观看| 91国产中文字幕| 精品国产超薄肉色丝袜足j| 久久精品亚洲av国产电影网| 午夜视频精品福利| 午夜老司机福利片| 亚洲成人免费av在线播放| 欧美黄色淫秽网站| 国产真人三级小视频在线观看| 亚洲avbb在线观看| 久久中文看片网| 久久久久久久久免费视频了| 亚洲熟妇中文字幕五十中出 | 久久人妻熟女aⅴ| 757午夜福利合集在线观看| 午夜福利免费观看在线| 人人澡人人妻人| 亚洲视频免费观看视频| 成人亚洲精品av一区二区 | 日本wwww免费看| 亚洲精品中文字幕在线视频| 一个人观看的视频www高清免费观看 | 亚洲国产精品sss在线观看 | 一级毛片高清免费大全| 另类亚洲欧美激情| 少妇的丰满在线观看| 91字幕亚洲| 国产成人影院久久av| 欧美 亚洲 国产 日韩一| 久久久国产精品麻豆| 人人澡人人妻人| 一区福利在线观看| 极品人妻少妇av视频| 999精品在线视频| 国产成人影院久久av| 久久久久久免费高清国产稀缺| 国产av又大| 天天躁夜夜躁狠狠躁躁| www国产在线视频色| 国产主播在线观看一区二区| 国产成人av激情在线播放| 国产精品九九99| 国产亚洲精品综合一区在线观看 | 天堂俺去俺来也www色官网| 男人操女人黄网站| 亚洲av成人不卡在线观看播放网| 精品欧美一区二区三区在线| 国产免费av片在线观看野外av| xxx96com| 精品久久久久久久毛片微露脸| 亚洲自偷自拍图片 自拍| 精品福利永久在线观看| 亚洲精品在线美女| 视频区图区小说| 日韩成人在线观看一区二区三区| 国内久久婷婷六月综合欲色啪| 欧美黑人欧美精品刺激| 99久久99久久久精品蜜桃| 亚洲性夜色夜夜综合| 久久久久国产精品人妻aⅴ院| 久久久久国内视频| 999久久久国产精品视频| 亚洲免费av在线视频| 美女午夜性视频免费| 国产精品永久免费网站| 天堂√8在线中文| 欧美日韩国产mv在线观看视频| 性色av乱码一区二区三区2| 亚洲欧美精品综合一区二区三区| 搡老熟女国产l中国老女人| 丝袜美腿诱惑在线| 欧美日韩精品网址| 亚洲色图 男人天堂 中文字幕| 午夜精品国产一区二区电影| 精品久久蜜臀av无| 宅男免费午夜| 午夜日韩欧美国产| 国产精品久久久久久人妻精品电影| 亚洲三区欧美一区| 精品久久久久久电影网| 精品国产一区二区三区四区第35| 国产aⅴ精品一区二区三区波| 国产一区二区在线av高清观看| 香蕉久久夜色| 久久精品91无色码中文字幕| 午夜精品国产一区二区电影| 欧美一级毛片孕妇| 人人妻人人爽人人添夜夜欢视频| 国产亚洲精品综合一区在线观看 | 女人被躁到高潮嗷嗷叫费观| 久久精品国产99精品国产亚洲性色 | 女人高潮潮喷娇喘18禁视频| 色尼玛亚洲综合影院| 老汉色av国产亚洲站长工具| 无限看片的www在线观看| 视频在线观看一区二区三区| 精品电影一区二区在线| 欧美成人免费av一区二区三区| a级片在线免费高清观看视频| 一级毛片高清免费大全| 亚洲黑人精品在线| 欧美日韩亚洲高清精品| 精品午夜福利视频在线观看一区| 国产精品二区激情视频| 国产成+人综合+亚洲专区| 中国美女看黄片| 日韩免费av在线播放| 久久久国产成人精品二区 | 中文字幕高清在线视频| 啪啪无遮挡十八禁网站| ponron亚洲| 自拍欧美九色日韩亚洲蝌蚪91| 亚洲av美国av| 国产成+人综合+亚洲专区| 满18在线观看网站| 欧美精品啪啪一区二区三区| 久久久久久久精品吃奶| 一区二区三区国产精品乱码| 一级a爱视频在线免费观看| 国产成人精品久久二区二区91| 高清毛片免费观看视频网站 | 男女做爰动态图高潮gif福利片 | 女人精品久久久久毛片| 免费少妇av软件| 国产成人啪精品午夜网站| 国产精品国产av在线观看| 亚洲精品国产色婷婷电影| 亚洲av美国av| 啦啦啦在线免费观看视频4| 色综合站精品国产| 一本综合久久免费| 99国产综合亚洲精品| a级毛片黄视频| www.www免费av| 黑人巨大精品欧美一区二区mp4| 后天国语完整版免费观看| 国产欧美日韩一区二区三区在线| 99热国产这里只有精品6| 99国产极品粉嫩在线观看| 99久久综合精品五月天人人| 另类亚洲欧美激情| 脱女人内裤的视频| 久久久久久大精品| 国产精品乱码一区二三区的特点 | 真人一进一出gif抽搐免费| ponron亚洲| 色婷婷av一区二区三区视频| 搡老岳熟女国产| 日本三级黄在线观看| 午夜免费观看网址| 精品国内亚洲2022精品成人| 午夜福利在线免费观看网站| 免费在线观看视频国产中文字幕亚洲| 久久中文字幕一级| 丝袜美足系列| 俄罗斯特黄特色一大片| 又黄又粗又硬又大视频| 欧美成人性av电影在线观看| 亚洲精品一卡2卡三卡4卡5卡| 久久九九热精品免费| 午夜精品国产一区二区电影| 亚洲欧美激情综合另类| 丁香欧美五月| 美女扒开内裤让男人捅视频| 午夜福利一区二区在线看| 最新美女视频免费是黄的| 宅男免费午夜| 久久 成人 亚洲| 女生性感内裤真人,穿戴方法视频| 在线国产一区二区在线| 国产有黄有色有爽视频| 日韩国内少妇激情av| 黄频高清免费视频| 欧美人与性动交α欧美软件| 亚洲国产精品一区二区三区在线| 欧美不卡视频在线免费观看 | 99热国产这里只有精品6| 亚洲精品在线观看二区| 精品久久蜜臀av无| 久热这里只有精品99| 国产在线精品亚洲第一网站| 亚洲熟妇熟女久久| 99久久99久久久精品蜜桃| 亚洲av第一区精品v没综合| 水蜜桃什么品种好| 国产精华一区二区三区| ponron亚洲| 亚洲成a人片在线一区二区| 午夜福利欧美成人| 91大片在线观看| 性色av乱码一区二区三区2| 国产高清视频在线播放一区| 成人18禁在线播放| 久久中文字幕一级| 麻豆久久精品国产亚洲av | 亚洲熟妇熟女久久| 国产精品免费视频内射| 十分钟在线观看高清视频www| 国产欧美日韩精品亚洲av| 国产乱人伦免费视频| 免费在线观看亚洲国产| 欧美黑人欧美精品刺激| 曰老女人黄片| 性少妇av在线| 99国产精品免费福利视频| 国产乱人伦免费视频| 亚洲成a人片在线一区二区| 亚洲精品美女久久久久99蜜臀| 97人妻天天添夜夜摸| 亚洲免费av在线视频| 久久久水蜜桃国产精品网| 少妇 在线观看| 少妇的丰满在线观看| 五月开心婷婷网| 日韩中文字幕欧美一区二区| av网站在线播放免费| 成人亚洲精品一区在线观看| 久久精品91蜜桃| 国产精品久久电影中文字幕| 俄罗斯特黄特色一大片| 成人av一区二区三区在线看| 国产高清videossex| 性色av乱码一区二区三区2| 好男人电影高清在线观看| 中文字幕最新亚洲高清| 欧美成人性av电影在线观看| 国产精品影院久久| 人妻丰满熟妇av一区二区三区| 久久天躁狠狠躁夜夜2o2o|